# Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age

> **NCT00893373** · PHASE2 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 276 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** sorafenib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00893373
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-11
- **Final completion:** 2014-09
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00893373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00893373, "Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00893373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*